Salute e Benessere

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides…

ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year HighlightsTotal revenue of $8.7 million in the fourth quarter of 2024, a...
Nasdaq GlobeNewswire
11/03/2025

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for…

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized Phase 2 trial evaluating OSE2101 (Tedopi®) with FOLFIRI in Advanced Pancreatic CancerDetailed results to be presented at upcoming medical congresses NANTES, France – March 11, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and the GERCOR Grouptoday announced...
Nasdaq GlobeNewswire
11/03/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of February 28, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (March 11, 2025 - 6:00 pm)– As of February 28, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
11/03/2025

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post…

Søren Tulstrup, President and CEO, Hansa Biopharma, said, "The PAES study is an important part of Hansa's continued commitment to ensuring access to potentially lifesaving IDEFIRIX therapy for highly sensitized kidney transplant patients, as we believe that the evidence generated will support the submission for full authorization in the European Union. Those considered highly sensitized and waiting for a transplant continue to face very long wait times due to their immunological status…
PR Newswire
11/03/2025

Medical Humidifier Market worth US$1,211.7 million by 2029 with 5.6% CAGR |…

Browse in-depth TOC on "Medical Humidifier Market" Browse in-depth TOC on "Medical Humidifier Market" 265 - Tables 60 - Figures 293 - Pages By Based on product,the medical humidifier market is segmented into Heated Humidifier, Bubble Humidifier, Heat and Moisture Exchangers (HMEs), and Humidifier Accessories. Among these, in 2023, Heat and Moisture Exchangers (HMEs) segment accounts for the highest growth rate in the Medical humidifier market. This is due to increasing...
PR Newswire
11/03/2025

United Legwear & Apparel Co. (ULAC) Expands UK & EU Presence with Strategic…

"We are strengthening our foundation in Europe with a clear vision for the future," said Hottot. "Bringing Tony on board is a pivotal step in scaling our operations, enhancing our market presence, and delivering even greater value to our retail partners. His extensive experience with global brands like Armani, Hugo Boss, Escada, and G-Star Raw positions him as a key driver of our continued success." "We are strengthening our foundation inEuropewith a clear vision for the…
PR Newswire
11/03/2025

Robotic Radiotherapy Market is expected to generate a revenue of USD 2.95…

The Robotic Radiotherapy Market is experiencing rapid growth due to increasing demand for non-invasive cancer treatments. Robotics and AI-driven technologies are transforming the field of oncology, enabling targeted tumor eradication while minimizing damage to surrounding healthy tissues. As healthcare facilities embrace automation, the market is set to expand, offering improved treatment efficiency and accuracy. The Robotic Radiotherapy Market is experiencing rapid growth due to increasing...
PR Newswire
11/03/2025

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology…

Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company's last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step – transforming into a fully unified health...
Nasdaq GlobeNewswire
11/03/2025

openRxiv Launch to Sustain and Expand Preprint Sharing in Life and Health…

Sustaining and Expanding the Role of Preprints in ScienceSince their launches in 2013 and 2019, respectively, preprint servers bioRxiv and medRxiv have transformed how scientific findings are communicated. They have hosted more than 325,000 reports of new discoveries, enabling scientists worldwide to collaborate, iterate, and build upon each other's work at an unprecedented pace. These platforms play a critical role during global challenges in health and research, such as the COVID-19 pandemic…
PR Newswire
11/03/2025

Milliken & Company Named One of the 2025 World's Most Ethical Companies®

"Our consistent inclusion on the World's Most Ethical Companies list reflects the collective efforts of our associates worldwide who embody our core values," said Halsey Cook, President and CEO of Milliken & Company. "We are grateful to once again be recognized by Ethisphere and stand firm in our resolve to uphold the highest standards of ethics across our operations." "Our consistent inclusion on the World's Most Ethical Companies list reflects the collective…
PR Newswire
11/03/2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late…

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S 1 Felzartamab, with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen's late-stage immunology portfolioCAMBRIDGE, Mass., March11, 2025(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq:...
Nasdaq GlobeNewswire
11/03/2025

Invitation to the Annual General Meeting

The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Thursday April 3, 2025 at 4:00 pm CEST at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark.For further information, please read the attached PDF documents. Attachments 2025_11_Invitation_to_the_2025_Annnual_General_MeetingAppendix A_Invitation_to_convene_the_Annual_General_Meeting_2025
Nasdaq GlobeNewswire
11/03/2025

Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene…

Tilray Craft, a new brand extension of the Tilray Medical brand within its medical cannabis portfolio in Germany.Tilray Craft is being introduced to address the evolving needs of patients in Germany for flower-based medical cannabis. The brand aims to offer unique flower options that are not currently available in the market, particularly targeting patients who require medical cannabis flower with higher THC and higher terpene content derived from novel genetic lineages. The latest product...
Nasdaq GlobeNewswire
11/03/2025

Caristo Secures FDA Clearance, Ushering in a New Era of AI-Powered Heart Attack…

The CaRi-Plaque technology supports non-invasive analysis of coronary anatomy and pathology from routine coronary computed tomography angiography (CCTA) scans to determine the presence, extent and severity of coronary plaques and luminal stenosis (narrowing of arteries). CaRi-Plaque builds on Caristo's breakthrough core CaRi-Heart® technology, which a landmark Lancet 2024 study proved can reveal hidden, high-risk markers of CAD progression — predicting heart attacks up to a decade before they…
PR Newswire
11/03/2025

Endo Announces Divestiture of International Pharmaceuticals Business

"This divestiture is an important step forward in our strategic transformation and focus on investing in our core-growth assets," said Scott Hirsch, Interim CEO of Endo. "We are confident that Paladin is well positioned for continued success in the Canadian market and that Knight Therapeutics is the right partner for Paladin's next chapter. We are grateful to the talented Paladin team for their dedication and many contributions." "This divestiture is an important step…
PR Newswire
11/03/2025

Neuromod Closes €10 Million Financing to Accelerate Commercialisation

Oversubscribed Financing to Drive Commercialisation Neuromod has raised €10 million of equity in an expansion of its Series B fundraisings. The financing was oversubscribed and was led by existing investors Fountain Healthcare Partners and Panakès Partners, backing Neuromod's mission to advance tinnitus care for patients globally. Neuromod has been making Lenire available through audiology and ENT practices throughout theUSAandEurope. Proceeds from the financing will be...
PR Newswire
11/03/2025

Orion Group Financial Statement documents 2024 and Remuneration Report published

ORION CORPORATIONSTOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 11 MARCH 2025 at 11.15 EET Orion Group Financial Statement documents 2024 and Remuneration Report published Orion Group's Financial Statement documents for 2024 have been published. The documents are available in Finnish and English on the Company's website athttps://www.orionpharma.com/annual-reportsand are attached to this release. Financial Statement documents include the company's Financial...
Nasdaq GlobeNewswire
11/03/2025

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical…

An De Vriese is currently Head of the Division of Nephrology and Infectious Disease in AZ Sint-Jan Brugge and Guest Professor at Ghent University, while Monnie Wasse serves as the Interim Chair of the Department of Internal Medicine, and the Chief of Nephrology and Director of Interventional Nephrology at the Rush University Medical Center. Both add considerable clinical nephrology expertise to the Company's esteemed and decorated MAB and will work alongside current members to offer strategic…
PR Newswire
11/03/2025

Orion Corporation: Managers' transactions – Liisa Hurme

ORION CORPORATIONMANAGERS' TRANSACTIONS11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
11/03/2025

Orion Corporation: Managers' transactions – René Lindell

ORION CORPORATIONMANAGERS' TRANSACTIONS11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – René Lindell Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
11/03/2025

Orion Corporation: Managers' transactions – Hao Pan

ORION CORPORATIONMANAGERS' TRANSACTIONS11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
11/03/2025

Orion Corporation: Managers' transactions – Olli Huotari

ORION CORPORATIONMANAGERS' TRANSACTIONS11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
11/03/2025

Medit Set to Launch a New Intraoral Scanner, Medit i900 classic

Moreover, Medit i900 classic also comes with an innovative and brand new All-on-X workflow solution, Medit SmartX. It is Medit's latest workflow solution to simplify the All-on-X digital workflow from start to finish, eliminating the need for additional hardware and software. Dentists who owns i900Family, i700, i700w, and i600 can also access to this new All-on-X workflow with a simple software update. Moreover, Mediti 900 classic also comes with an innovative and brand new All-on-X workflow...
PR Newswire
11/03/2025

Orion Corporation: Managers' transactions – Julia Macharey

ORION CORPORATIONMANAGERS' TRANSACTIONS11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Julia Macharey Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
11/03/2025
Altri  Comunicati